October 25, 2011

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Key Points

Key points are not available for this paper at this time.

Abstract

MK-2206 was well tolerated, with evidence of AKT signaling blockade. Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.

AI에게 질문

Bookmark

AI에게 질문

Bookmark

Cite This Study

Yap et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8d4b32c87b79b92d17cf3 https://doi.org/https://doi.org/10.1200/jco.2011.35.5263

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)2001 · 1,832 citations
2Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor2009 · 15 citations
3How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development2003 · 152 citations
4High-throughput oncogene mutation profiling in human cancer2007 · 996 citations
5Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers2008 · 1,330 citations